Skip to main content

  • Skip to main menu
  • Skip to user menu
    • Login|
    • Employer Login
BioSpace logo
    • Clinical Research
    • Finance
    • Covid-19
    • See all news
    • Search jobs
    • Job alerts
    • Biotech Bay
    • Genetown
    • Biotech Beach
    • BioMidwest
    • Pharm Country
    • See all regions
  • Career Resources
  • Newsletters
  • Company Profiles
  • Advertise
  • Biotech Bay
  • Biotech Beach
  • BioCapital
  • BioMidwest
  • Bio NC
  • BioForest
  • Genetown
  • Best Places to Work
  • Pharm Country
  • Lone Star Bio
  • NextGen Bio

Filter News

  • All (784,968)
  • Topic (743,269)
  • Hotbed/Location (715,496)
  • Career Advice (3,842)
  • Insights (146)

Biogen Idec, Elan Plummet On Withdrawal Of Tysabri

Published: Mar 02, 2005

Two serious adverse events - one ending in death - was enough for Biogen Idec Inc. and Elan Corp. plc to suspend marketing of their multiple sclerosis drug, Tysabri, just three months after FDA approval.

Related links

  • BioWorld International This will open in a new window
  • Email this
  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Reddit

Back to news

Back to top

    Explore
    • News
    • Jobs
    • Career Advice
    • Newsletters
    • Therapeutic Insights
    • RSS Feeds
    • Events
    • Company Profiles
    Hotbeds
    • Biotech Bay
    • Biotech Beach
    • BioCapital
    • BioMidwest
    • Bio NC
    • BioForest
    • Genetown
    • Best Places to Work
    • Pharm Country
    • Lone Star Bio
    • NextGen Bio
    About
    • About Us
    • Contributors
    • Support
    • Join Our Team
    • Terms & Conditions
    • Privacy Policy
    Employers
    • Employer Login
    • Unlimited Jobs
    • Job Postings
    • Hotbed Placements
    • Recruitment Services
    • Submit a Press Release
    • PR Solutions
    • Employer Insights
    • Talent Connect
    • Contact Us
    • Facebook
    • Twitter
    • LinkedIn

© 1985 - 2023 BioSpace.com. All rights reserved. Powered by Madgex Job Board Software